title: Collagen corneal shields.
abstract: Collagen corneal shields were developed as a corneal bandage lens and are currently indicated for ocular surface protection following surgery and in traumatic and nontraumatic corneal conditions. Collagen shields are manufactured from porcine or bovine collagen and three different collagen shields are currently available with dissolution times of 12, 24, and 72 hours. The theoretical, experimental, and clinical evidence supports a role for collagen corneal shields as a drug delivery device and in the promotion of epithelial and stromal healing. Presoaking the collagen shield in a pharmacological agent with adjunctive topical treatment represents the most efficacious method of utilizing collagen shields for drug delivery. In microbial keratitis collagen shields can enhance drug delivery, promote epithelial and stromal healing, neutralize collagenases, and reduce corneal inflammation. This review will examine the evidence that supports the role of collagen shields in drug delivery and corneal wound healing. Despite a large volume of experimental (animal) work, studies on human subjects, particularly randomized controlled trials, are lacking. The authors are advocating the reassessment of the application and benefits of corneal collagen shields to clinical practice.
authors.affiliation: St Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, United Kingdom.
authors.forename: C E
authors.initials: CE
authors.lastname: Willoughby
authors.forename: M
authors.initials: M
authors.lastname: Batterbury
authors.forename: S B
authors.initials: SB
authors.lastname: Kaye
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D001672:Biocompatible Materials; D001684:Biological Dressings; D003094:Collagen; D003261:Contact Lenses; D003316:Corneal Diseases / Q000628:therapy*; D016503:Drug Delivery Systems; D006801:Humans
chemical_list: D000900:Anti-Bacterial Agents; D001672:Biocompatible Materials; D003094:Collagen